Trial
NCT04346615
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
COVID-19 Infection
Intervention
Zavegepant (BHV-3500)
Why stopped
Lack of enrollment due to evolution of COVID-19 pandemic with reduction in patients at risk for severe disease and growing number of effective alternative therapies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-02